Resumen de acción 524715 Sun Pharmaceutical Industries Limited, empresa farmacéutica de genéricos, desarrolla, fabrica y comercializa formulaciones de marca y genéricas e ingredientes farmacéuticos activos (API) en India y a escala internacional. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Sun Pharmaceutical Industries Limited Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Sun Pharmaceutical Industries Precios históricos de las acciones Precio actual de la acción ₹1,861.70 Máximo en las últimas 52 semanas ₹1,960.20 Mínimo de 52 semanas ₹1,252.65 Beta 0.60 Cambio en 1 mes 6.41% Variación en 3 meses -4.47% Cambio de 1 año 47.75% Variación en 3 años 120.22% Variación en 5 años 318.92% Variación desde la OPV 23,922.00%
Noticias y actualizaciones recientes
Orexo Resolves Zubsolv US Patent Litigation with Sun Pharmaceutical Industries Dec 16
Price target increased by 8.8% to ₹2,023 Oct 30
Second quarter 2025 earnings: EPS exceeds analyst expectations Oct 29 Sun Pharma Presents LEQSELVI (deuruxolitinib) Data Highlighting Clinical Efficacy & Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference
Sun Pharma Announces Multiple Data Presentations Highlighting Its Dermatology Portfolio to Be Featured At the 2024 Fall Clinical Dermatology Conference Oct 25
Sun Pharma Appoints Tejash Chheda as General Manager - Head of Media Sep 20 Ver más actualizaciones
Orexo Resolves Zubsolv US Patent Litigation with Sun Pharmaceutical Industries Dec 16
Price target increased by 8.8% to ₹2,023 Oct 30
Second quarter 2025 earnings: EPS exceeds analyst expectations Oct 29 Sun Pharma Presents LEQSELVI (deuruxolitinib) Data Highlighting Clinical Efficacy & Durability for Treatment of Alopecia Areata at the 2024 Fall Clinical Dermatology Conference
Sun Pharma Announces Multiple Data Presentations Highlighting Its Dermatology Portfolio to Be Featured At the 2024 Fall Clinical Dermatology Conference Oct 25
Sun Pharma Appoints Tejash Chheda as General Manager - Head of Media Sep 20
Sun Pharma Introduces Novel Treatment, Tedizolid Phosphate in India for Acute Bacterial Skin and Skin Structure Infection Aug 23
Sun Pharmaceutical Industries Limited Approves Final Dividend for the Financial Year 2023-2024 Aug 06
Price target increased by 7.0% to ₹1,749 Aug 05
Price target increased by 7.2% to ₹1,746 Aug 04
Sun Pharmaceutical Industries Limited Receives Approval from U.S. Food and Drug Administration for LEQSELVITM (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata Jul 26
Sun Pharmaceutical Industries Limited to Report Q1, 2025 Results on Aug 01, 2024 Jul 16
Full year 2024 earnings: EPS exceeds analyst expectations Jul 10
Upcoming dividend of ₹5.00 per share Jul 05
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) from Krensavage Asset Management, LLC and others for approximately Jun 25
Sun Pharmaceutical Industries Limited Announces Results from A Phase 1, Multiple Ascending-Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Gl0034 (Utreglutide) in Obese Adults Jun 24
Sun Pharmaceutical Industries Limited, Annual General Meeting, Aug 05, 2024 Jun 20
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 9.61% stake in HaystackAnalytics Pvt. Ltd. for INR 330 million. Jun 08
Full year 2024 earnings: EPS exceeds analyst expectations May 23
Sun Pharmaceutical Industries Limited to Report Q4, 2024 Results on May 22, 2024 May 15
Sun Pharmaceutical Industries Limited Announces Executive Changes Apr 03
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) agreed to acquire 16.33% stake in Surgimatix, Inc for $3.1 million. Feb 20
Dividend increased to ₹8.50 Feb 02
Price target increased by 9.3% to ₹1,453 Feb 01
Third quarter 2024 earnings: EPS exceeds analyst expectations Feb 01
Sun Pharmaceutical Industries Limited Approves Interim Dividend for the Financial Year 2023-24, Payable on or Before February 23, 2024 Jan 31
Sun Pharmaceutical Industries Limited to Report Q3, 2024 Results on Jan 31, 2024 Jan 16
Sun Pharma Raises Offer to Buy Taro Pharmaceutical Industries' US Arm Dec 13
Sun Pharmaceutical Industries Limited Announces Management Changes Dec 07
Second quarter 2024 earnings: EPS exceeds analyst expectations Nov 02
Sun Pharmaceutical Industries Limited to Report Q2, 2024 Results on Nov 01, 2023 Oct 14
Sun Pharmaceutical Industries Limited Announces Presentation of Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Oct 13
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 37.76% stake in EzeRx Health Tech Pvt. Ltd. for INR 290 million. Oct 06
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) signed a binding letter of intent to acquire remaining 25% stake in Sun Pharma de México, S.A. de C.V. from Indi Pharma S.A.P.I. de C.V. for approximately MXN 160 million. Sep 29
Sun Pharmaceutical Industries Limited Approves Final Dividend for the Financial Year 2022-2023 Aug 30
Sun Pharmaceutical Industries Limited Declares Final Dividend for the Financial Year 2022-2023 Aug 29
Sun Pharmaceutical Industries Looking to Fully Acquire Its Israel-Based Unit Taro Pharmaceutical Industries Aug 28
Price target increased by 7.0% to ₹1,229 Aug 07
Full year 2023 earnings: Revenues and EPS in line with analyst expectations Jul 30
Sun Pharmaceutical Industries Limited Appealed the Patent Litigation Decision Issued by the US District Court for the District of New Jersey Relating to Orexo's Patents Protecting ZUBSOLV® Jul 24
Upcoming dividend of ₹4.00 per share at 1.0% yield Jul 21
High number of new directors Jul 18
Sun Pharmaceutical Industries Limited to Report Q1, 2024 Results on Aug 03, 2023 Jul 12 Sun Pharmaceutical Industries Limited Propose Final Dividend for Fy2022-23, Payable on or Before September 8, 2023
Orexo AB (publ) Wins Patent Litigation for ZUBSOLV in the US Against Sun Pharmaceutical Industries Limited Jul 03
Sun Pharma Canada Inc. Announces Health Canada Approval of (PR)ABSORICA LD®? (Isotretinoin Capsules) for Treatment of Severe Nodular Acne Jun 27
Sun Pharmaceutical Industries Ltd. Presents Data from First-In-Human Phase 1 Studies of Gl0034 At the American Diabetes Association 83Rd Scientific Sessions Jun 26
Full year 2023 earnings: Revenues and EPS in line with analyst expectations May 27 Sun Pharmaceutical Industries Limited Announces Board Appointments
Sun Pharmaceutical Industries Limited to Report Q4, 2023 Results on May 26, 2023 May 12
Sun Pharmaceutical Industries Limited Provides Deuruxolitinib Clinical Program Update May 04
Whole Time Director recently sold ₹3.9m worth of stock Mar 22
Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) entered into agreement to acquire 27.39% stake in Remidio Innovative Solutions Pvt. Ltd. for INR 1.5 billion. Feb 20
Sun Pharmaceutical Industries Limited Announces US FDA Approval for Generic Lenalidomide Capsules Feb 11
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Feb 01 Sun Pharmaceutical Industries Limited Announces Retirement of Kalyanasundaram Subramanian as Whole-Time Director, Effective February 13, 2023
Sun Pharmaceutical Industries Limited Launches SEZABYTM (Phenobarbital Sodium) in the U.S. for the Treatment of Neonatal Seizures Jan 26
Sun Pharmaceutical Industries Limited to Report Q3, 2023 Results on Jan 31, 2023 Jan 17
Sun Pharmaceutical Industries Limited Announces One of Its Wholly-Owned Subsidiaries Launch A Novel Anti-Cancer Drug, Palbociclib in India for Patients Jan 12
Aurinia Pharmaceuticals Inc. Enters into Settlement Agreement with Sun Pharmaceutical Industries, Inc., Sun Pharmaceuticals Industries, Ltd., and Sun Pharma Global FZE Jan 04
Whole Time Director recently sold ₹9.2m worth of stock Dec 28
Insider recently sold ₹3.1m worth of stock Dec 10
Whole Time Director recently sold ₹10m worth of stock Nov 27
Sun Pharmaceutical Industries Limited and Sun Pharma Advanced Research Company Limited Announces U.S. FDA Approval of SEZABY (Phenobarbital Sodium Powder for Injection) for the Treatment of Neonatal Seizures Nov 19
Second quarter 2023 earnings: EPS exceeds analyst expectations Nov 02
Sun Pharmaceutical Industries Limited Approves the Appointment of Sanjay Asher as an Additional Director Designated as an Independent Director Nov 02
Sun Pharmaceutical Industries Limited to Report Q2, 2023 Results on Nov 01, 2022 Oct 11
Whole Time Director recently sold ₹14m worth of stock Sep 24
Upcoming dividend of ₹3.00 per share Aug 12
Sun Pharmaceutical Industries Limited Announces Retirement of Israel Makov as Chairman and Member of the Board Aug 05 Sun Pharmaceutical Industries Limited Recommends Final Dividend for the Year 2021-22, Payable on or Before September 20, 2022
First quarter 2023 earnings: EPS and revenues exceed analyst expectations Jul 30
Sun Pharmaceutical Industries Limited to Report Q1, 2023 Results on Jul 29, 2022 Jul 13
Sun Pharmaceutical Industries Limited Announces Cessation of Mr. Ashok I Bhuta as Compliance Officer Jun 02
Sun Pharmaceutical Industries Limited Recommends Final Dividend for the Year Ended March 31, 2022 May 31
Full year 2022 earnings: EPS misses analyst expectations May 31
Sun Pharmaceutical Industries Limited to Launch Brillo® in India May 19
Sun Pharmaceutical Industries Limited to Report Q4, 2022 Results on May 30, 2022 May 16
Executive Director recently sold ₹1.8m worth of stock Apr 03
Executive Director recently sold ₹14m worth of stock Mar 23 Sun Pharmaceutical Industries Limited Announces Change of Company Secretary and Compliance Officer
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Feb 01
Sun Pharma Receives DCGI Approval for Molxvir® (Molnupiravir) in India Dec 29
Whole Time Director recently sold ₹4.0m worth of stock Dec 28
A Federal Judge Denies All Motions for Summary Judgment in a Lawsuit Against Sun Pharmaceutical Industries Ltd and Ranbaxy Inc. in Generic Drug Overpricing Lawsuit Nov 24
Second quarter 2022 earnings released: EPS ₹8.50 (vs ₹7.56 in 2Q 2021) Nov 03
Whole Time Director recently sold ₹45m worth of stock Oct 03
Sun Pharma Launches Chericof® 12 in India, A Novel Formulation That Provides Relief from Cough for Up to 12 Hours Sep 30
Insider recently sold ₹167k worth of stock Sep 22
Non-Executive & Independent Director Vivek Sehgal has left the company Sep 08
Upcoming dividend of ₹2.00 per share Aug 16
Insider recently sold ₹1.0m worth of stock Aug 12
Price target increased to ₹826 Aug 03 Rentabilidad de los accionistas 524715 IN Pharmaceuticals Mercado IN 7D 2.9% 1.7% 0.2% 1Y 47.8% 39.1% 17.2%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: 524715 superó a la industria Indian Pharmaceuticals, que obtuvo un rendimiento del 39.1% el año pasado.
Rentabilidad vs. Mercado: 524715 superó al mercado Indian, que obtuvo un rendimiento del 17.2% el año pasado.
Volatilidad de los precios Is 524715's price volatile compared to industry and market? 524715 volatility 524715 Average Weekly Movement 2.5% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.2% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.1%
Precio estable de las acciones: 524715 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de 524715 (2%) se ha mantenido estable durante el año pasado.
Acerca de la empresa Sun Pharmaceutical Industries Limited, una empresa farmacéutica de genéricos, desarrolla, fabrica y comercializa formulaciones de marca y genéricas e ingredientes farmacéuticos activos (API) en India y a escala internacional. La empresa ofrece formulaciones en diversas áreas terapéuticas, como sistema nervioso central, dermatología, cardiología, oncología, neuropsiquiatría, gastroenterología, antiinfecciosos, diabetología, analgésicos, vitaminas, minerales y nutrientes, respiratorio, ginecología, urología, oftalmología, ortopedia, nefrología, odontología y otras áreas. Proporciona API para anticancerígenos, péptidos, esteroides, hormonas y medicamentos inmunosupresores.
Mostrar más Resumen de fundamentos de Sun Pharmaceutical Industries Limited ¿Cómo se comparan los beneficios e ingresos de Sun Pharmaceutical Industries con su capitalización de mercado? Estadísticas fundamentales de 524715 Capitalización bursátil ₹4.47t Beneficios(TTM ) ₹110.54b Ingresos (TTM ) ₹503.08b
40.4x Ratio precio-beneficio (PE)
8.9x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de 524715 Ingresos ₹503.08b Coste de los ingresos ₹112.67b Beneficio bruto ₹390.41b Otros gastos ₹279.87b Beneficios ₹110.54b
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) 46.07 Margen bruto 77.60% Margen de beneficio neto 21.97% Ratio deuda/patrimonio 3.0%
¿Cómo se ha desempeñado 524715 a largo plazo?
Ver rendimiento histórico y comparativa Dividendos
0.7% Rentabilidad actual por dividendo
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/27 05:01 Precio de las acciones al final del día 2024/12/27 00:00 Beneficios 2024/09/30 Ingresos anuales 2024/03/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas Sun Pharmaceutical Industries Limited está cubierta por 73 analistas. 36 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Nitin Bhasin Ambit Capital Prashant Nair Ambit Capital null null Anand Rathi Shares and Stock Brokers Limited
Mostrar 70 más analistas 
